Fecal transplant to fight drug resistance in liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help your liver cancer become sensitive again to treatment that has stopped working. It may help reverse drug resistance and improve outcomes for people with advanced liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your liver cancer has continued to grow after receiving the standard triple therapy (TACE, lenvatinib, and sintilimab).
- You have a liver tumor that can be measured on a scan (at least 10 mm wide).
- Your doctor expects you to live more than 3 months.
- You have moderate liver function (Child-Pugh class A or B) and are in fairly good overall health (able to care for yourself).
- You are between 18 and 75 years old.
- You have not had a fecal transplant or taken probiotics since your cancer diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This trial tests whether giving a fecal transplant (a procedure that replaces the bacteria in your gut) can help people with advanced liver cancer whose current treatment has stopped working. It may help boost your immune system to fight the cancer.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests combining a fecal transplant (healthy donor bacteria) with two drugs—QL1706 (an immunotherapy) and bevacizumab (a blood vessel blocker)—for people with advanced liver cancer that hasn't been treated before. The goal is to see if this combination can shrink tumors or slow their growth.
This trial studies fecal microbiota transplantation (a transfer of healthy gut bacteria from a donor) to help people with worsening liver failure. It may help by changing gut bacteria, which can affect complications like confusion, fluid buildup, infections, and kidney problems.
This trial tests a new combination treatment (PULSAR plus fecal microbiota transplant) for people with advanced liver cancer that stopped responding to initial therapy. It aims to see if this approach can help control the cancer again.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.